MiRNA Dysregulation in Childhood Hematological Cancer

Oliveira, Jaqueline Carvalho de; Roberto, Gabriela Molinari; Baroni, Mirella; Salomão, Karina Bezerra; Pezuk, Julia Alejandra; Brassesco, María Sol

doi:10.3390/ijms19092688

Cited by 24 publications

(28 citation statements)

References 233 publications

(276 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, we noticed some reviews focused on miRNAs in childhood ALL have mentioned miR-100, miR-210, and miR-146a in common. 8,9 In our further literation retrieval, miR-100, 10,11 miR-146a, 12,13 as well as miR-210 14,15 were all reported to have remarkable significance in ALL for several times, especially in pediatric ALL. For example, the restoration of miR-100 in ALL cells suppressed cell proliferation and increased dexamethasone-induced cell apoptosis, 16 while miR-146a was reported to be highly expressed in pediatric ALL bone marrow samples.…”

Section: Introductionmentioning

confidence: 76%

“…24,25 Through our literature review, we found some influential review focused on miRNAs in childhood ALL have mentioned miR-100, miR-210, and miR-146a in common. 8,9 In the present study, we focused on genetic variants of miR-100, miR-146a, and miR-210, which were all demonstrated to be participate in carcinogenesis of ALL, 13,14,16 and investigated their association with susceptibility of childhood ALL. Among them, rs7395206 have never been reported in other studies while rs543412 and rs2910164 has not been detected in Chinese childhood ALL groups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A genetic variant in miR‐100 is a protective factor of childhood acute lymphoblastic leukemia

Xue

Yang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background In the past decade, miR‐100, miR‐146a, and miR‐210 were reported to be dysregulated in childhood acute lymphoblastic leukemia (ALL). However, effects of genetic variants in these three microRNAs have not been investigated in Chinese population. Methods In this study, we conducted a case‐control study to evaluate the relationship between genetic variants in miR‐100, miR‐146a, and miR‐210 and the risk of childhood ALL in Chinese population. Subsequently, plasma expression level of miR‐100 was also detected. Result We found that subjects carrying mutant homozygous TT genotype of miR‐100 rs543412 had a statistically significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.73, 95% confidence interval [CI] = 0.55‐0.97, P = 0.029). This protective effect was also observed among subjects whose parents were ever drinkers (adjusted OR = 0.53, 95% CI = 0.29‐0.94), or whose living house were ever painted (adjusted OR = 0.57, 95% CI = 0.34‐0.94). Besides, rs543412 variant homozygous TT had a significantly protective role in patients with childhood B‐ALL. Finally, we found that expression level of miR‐100 in plasma of childhood ALL cases was significantly higher than that of noncancer controls. Conclusion Our study suggested that there was significant association between the polymorphisms in miR‐100 (rs543412) and decreased susceptibility to childhood ALL.

show abstract

Section: Introductionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

A genetic variant in miR‐100 is a protective factor of childhood acute lymphoblastic leukemia

Xue

Yang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…These micro markers have proven to be very promising chALL biomarkers and have widespread clinical applications because of their stability and resistance to degradation in not only blood, but also various biological specimens (such as tissue, sputum, stool and formalin-fixed paraffin-embedded (FFPE) specimens), easily measured, and most importantly, their quantities correlates with the presence of the malignancy or with clinically relevant malignancy features (8,14,(95)(96)(97). Recent studies have revealed that extracellular circulating miRNA levels in secreted membrane vesicles (microvesicles and exosomes), blood serum, and other body fluids can be used as biomarkers to diagnose, classify and predict prognosis of chALL (96,(98)(99)(100)(101). miRNA expression dysregulation in cancers is because of different mechanisms, such as deletion or amplification of miRNA related genes, abnormal transcriptional control of miRNAs, epigenetic dysregulation and defects in the biogenesis machinery of miRNA (102).…”

Section: Mirna Levels Alterationmentioning

confidence: 99%

“…Some tumor suppressor miRNAs are miR-181a, miR-326, and miR-200c, which show frequently down-regulation in chALL (97,98). MicroRNA profiling can also be correlated with relevant clinical information, such as disease aggressiveness and metastatic potential, patient response to therapy, time-to-relapse and OS, and other clinical markers in chALL (101). Based on some investigations, not only can miRNAs regulate and sensitize the MDR phenotype, but also can be served as prognostic markers with potential implications in therapeutic interventions as drugs or therapeutic targets in chALL (103).…”

Section: Mirna Levels Alterationmentioning

confidence: 99%

Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia

et al. 2020

View full text Add to dashboard Cite

Biomarkers are biological molecules found in body fluids or tissues, which can be considered as indications of a normal or abnormal process, or of a condition or disease. There are various types of biomarkers based on their application and molecular alterations. Treatment-sensitivity or drug resistance biomarkers include prognostic and predictive molecules with utmost importance in selecting appropriate treatment protocols and improving survival rates. Acute lymphoblastic leukemia (ALL) is the most prevalent hematological malignancy diagnosed in children with nearly 80% cure rate. Despite the favorable survival rates of childhood ALL (chALL), resistance to chemotherapeutic agents and, as a consequence, a dismal prognosis develops in a significant number of patients. Therefore, there are urgent needs to have robust, sensitive, and disease-specific molecular prognostic and predictive biomarkers, which could allow better risk classification and then better clinical results. In this article, we review the currently known drug resistance biomarkers, including somatic or germ line nucleic acids, epigenetic alterations, protein expressions and metabolic variations. Moreover, biomarkers with potential clinical applications are discussed.

show abstract

“…13 Many studies have shown that miRNAs may act as oncogenes or tumor suppressors, contributing to the development of malignant cells in both solid and hematological tumors, including AML. 14 It is believed that abnormal expression of some miRNAs may affect the process of development of leukemic cells or alter the response to treatment in cases of AML. Thus, the ability to reverse this abnormal expression may help influence disease outcome.…”

mentioning

confidence: 99%

Low expression of miR‐204 is associated with expression of CD34 and poor performance status in denovo AML

Abdelhafiz

El-Sayed

Saber

et al. 2020

Int J Lab Hematology

View full text Add to dashboard Cite

AML is the most common type of acute leukemia in adults, accounting for approximately 80% of adult cases of acute leukemia. 1 AML is generally recognized as disease of late age, with first-time diagnoses of AML made at 68 years of age on average. 2 Still, children account for 6% to 7% of cases of AML and have a biology that is quite different from that of adult patients. 3The disease arises from bone marrow stem cells which proliferate uncontrollably with impaired differentiation capacity, leading Abstract Introduction: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. There is growing evidence that microRNAs (miRNAs) provide prognostic information in AML. MiR-204 has a tumor suppressor function, and several studies have proven its role in solid cancers. The aim of this work is to evaluate the level of expression of miR-204 in adults newly diagnosed with AML with normal karyotype and to correlate its level of expression with disease outcome and different prognostic factors. Patients and methods: The study included 87 adult patients newly diagnosed with AML. Detection of miR-204 was done using RT-PCR in patients and seven agematched controls. Results: Acute myeloid leukemia patients showed significantly lower miR-204 expression, compared to control group (P = .029). Low miR-204 expression was significantly associated with positive CD34 (P = .017), with poor performance status (PS) (P = .009), and with the presence of diabetes mellitus (DM) (P = .014). Low expression of miR-204 was also significantly associated with shorter overall survival (OS) (P = .020) and disease-free survival (DFS) (P = .013). Low miR-204 expression was identified as an independent prognostic factor for prediction of shorter OS (P = .034) and DFS (P = .027) in AML. Conclusion: To the best of our knowledge; this is the first time to prove the correlation between miR-204 expression and CD34 expression. Further study of this correlation is needed to confirm the role of miR-204 in CD34-positive cells, including leukemic stem cells. This correlation may have therapeutic implications. MiR-204 can be used as a biomarker for PS in AML patients. K E Y W O R D S acute myeloid leukemia, CD34, leukemic stem cells, miR-204, performance status S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Abdelhafiz AS, Elsayed GM, Saber MM, Gameel A, Hamdy N. Low expression of miR-204 is associated with expression of CD34 and poor performance status in denovo AML. Int J Lab Hematol. 2020;42:263-269.

show abstract

MiRNA Dysregulation in Childhood Hematological Cancer

Cited by 24 publications

References 233 publications

A genetic variant in miR‐100 is a protective factor of childhood acute lymphoblastic leukemia

A genetic variant in miR‐100 is a protective factor of childhood acute lymphoblastic leukemia

Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia

Low expression of miR‐204 is associated with expression of CD34 and poor performance status in denovo AML

Contact Info

Product

Resources

About